Press Release

About Us
- Overview
- History
- Mission
- Team
- Contact Us
Our Science
- Our FoCus
- Our Publications
Pipeline
Partnerships
Press Release
- Press Release
- Media Coverage
Join Us
Legal Notice
Privacy Policy

Home page

2021-06

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

Shanghai, China—InxMed (Shanghai) Co., Ltd. (“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong University School of Medicine made an online publication on Advanced Science titled “Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling”.

2020-09

InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities

Nanjing, China—InxMed (Nanjing) Co., Ltd. (“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced the completion of its Series A+ financing of 130M RMB (~US$19Million). The financing was led by Ennovation Ventures and China Growth Capital and followed by InnoMed Capital and Grand Yangtze Capital.

2020-08

Interview of Zaiqi Wang – Chairman & CEO, InxMed by PharmaBoardroom

Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.

2020-06

InxMed Released Research Data of “FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition” at 2020 AACR Annual Meeting

SHANGHAI, June 24, 2020 -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact,

2020-03

InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States

Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.

2020-01

InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab January 07, 2020

Shanghai, China – InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced that the company

< 1 2 3 4 5 > proceed page

QUICK LINKS

About Us
- Overview
- History
- Mission
- Team
- Contact Us
Our Science
- Our FoCus
- Our Publications
Pipeline
Partnerships
Press Release
- Press Release
- Media Coverage
Join Us
Legal Notice
Privacy Policy

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

MESSAGE

SEO